ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

  • Abstract Number: 0269 • ACR Convergence 2025

    Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group

    Paula García-Escudero1, Marta López2, Berta Magallares3, Dolly Viviana Fiallo Suárez4, Diego Dios Santos5, César Antonio Egües Dubuc6, Santos Castañeda7, Alicia Garcia8, Isla Morante Bolado9, Elena María Oliver García10, Clara Garcia Belando11, Cristina Corrales12, Francisco Javier Toyos13, Judit Font-Urgelles14, Meritxell Salles Lizarzaburu15, Carolina Merino16, Irene Carrion17, Jose Angel Hernandez18, Lourdes Villalobos19, Alina-Lucica Boteanu20, Beatriz Frade Sosa21, cristiana Sieiro22, Irene Monjo Henry23, Ernesto Trallero24, Eugenia Enriquez25, Maria Rodriguez26, Elena Riera Alonso27, Marta Ibañez28, Delia Reina29, Rafael Benito Melero González30, Giuliano Boselli31, Alberto Mariano32, Ignacio Vázquez Gómez33, Jose Alberto Miranda34, Clara Moriano35, Elena Aurrecoechea36, Paloma Vela Casasempere37, Iñigo Rúa-Figueroa38 and Jaime Calvo39, 1Hospital Universitario Álava, Bilbao, Spain, 2Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, 3Hospital de Sant Pau, Bareclona, 4H.U. Doctor Negrín, Gran Canarias, 5C. H. U. A Coruña, A Coruña, Spain, 6Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, 7Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 8Rheumatologist, La Laguna, Spain, 9Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, 10H.C. U. Lozano Blesa, Zaragoza, 11H.C. U. Virgen de la arrizaca, Murcia, 12HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, 13Virgen Macarena University Hospital,, Sevilla, Spain, 14Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 15Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, 16Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, 17Hospital del Mar, Barcelona, Spain, 18Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, 19Ramon y Cajal Hospital, MADRID, Spain, 20H.U. Ramón y Cajal, Madrid, Spain, 21Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 22Univrsity of Manchester, Manchester, United Kingdom, 23Hospital Universitario La Paz, Madrid, Spain, 24H. U. Vall d'Hebron, Barcelona, 25Clínica Universidad de Navarra, Madrid, Spain, 26H. Clínico San Carlos, Madrid, Spain, 27Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 28Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 29Complex Hospitalari Moisès Broggi, Barcelona, Spain, 30C. H. U. de Ourense, Ourense, 31Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, 32Virgen del Rocío University Hospital, Sevilla, Spain, 33H.U. Doctor Peset, Valencia, 34C. H. U. Lucus Augusti, Lugo, Spain, 35Hospital León, LEON, Castilla y Leon, Spain, 36H. Sierrallana, Santander, 37Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 38Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, 39Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain

    Background/Purpose: VEXAS syndrome is a rare disease caused by somatic mutations in UBA1 gene. Different mutations in this gene appear to be associated with specific…
  • Abstract Number: 2018 • ACR Convergence 2025

    Investigating Epidemiology, Clinical associations, and Outcomes of Uveitis: A Retrospective Cohort Study

    Archit Srivastava1, Jayesh Valecha2, Sehreen Mumtaz1, Caroyln Harvey3, Florentina Berianu1 and Vikas Majithia4, 1Mayo Clinic Florida, Jacksonville, FL, 2Saint Vincent Hospital, Worchester, FL, 3Mayo Clinic, Phoenix, AZ, 4Mayo Clinic Hospital, Jacksonville, FL

    Background/Purpose: Uveitis is a significant cause of visual impairment in the U.S., with a prevalence of 438 per 100,000 persons [1]. It is anatomically classified…
  • Abstract Number: 0260 • ACR Convergence 2025

    Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

    Lachelle D. Weeks1, Danielle Hammond2, Sinisa Savic3, Mael Heiblig4, Onima Chowdhury5, Arsène Mekinian6, Carmelo Gurnari7, Radhakrishanan Ramchandren8, Sophie georgin-Lavialle9, Marcela ferrada10, Sarah A. Buckley11, Bryan G. harder11, Sandra Goble11, David Beck12 and Matthew Koster13, 1Dana Farber Cancer Institute, Boston, MA, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 4Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, 5Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, 6Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i3), Saint-Antoine University Hospital, 75012 Paris, France, Paris, France, 7Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, 8University of Pittsburgh Medical Center, Pittsburgh, PA, 9Sorbonne university, Tenon hospital, DMU3ID, CEREMAIA, ERN RITA, Paris, France, 10University of Maryland, Bethesda, MD, 11Sobi Inc., Waltham, MA, 12Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, 13Mayo Clinic, Rochester, MN

    Background/Purpose: VEXAS syndrome is a recently identified, severe systemic hemato-inflammatory disease with a complex and heterogeneous clinical presentation. The disease is associated with significant morbidity…
  • Abstract Number: 1787 • ACR Convergence 2025

    Spatial and Quantitative Semiautomated Image Analysis of Synovial Biopsies Studied Using a Novel High-Plex Immunofluorescence Platform

    Estefania Quesada-Masachs1, Luis Peñaranda Bolaño1, Aakriti Arora2, Jessica Murillo-Saich3, Edward Lo4, Tad George4, Daniel Tanoeihusada4, Sara McArdle5 and Monica Guma6, 1University of Miami, Miami, FL, 2University of Miami / Jackson Memorial Hospital, Miami, FL, 3University of California, San Diego, San Diego, CA, 4RareCyte, Seattle, WA, 5La Jolla Institute for Immunology, La Jolla, CA, 6University of California San Diego, San Diego, CA

    Background/Purpose: Although not part of the formal ACR criteria for RA, PsA, or OA, synovial pathology can be a helpful tool in clinical practice. Histopathologic…
  • Abstract Number: 0252 • ACR Convergence 2025

    Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH

    María Paula Carrillo1, Juan Esteban Bedoya-Loaiza1, Claudia Ibáñez-Antequera1, Laura Gallego1, Alejandro Escobar1, Adriana Rojas-Villarraga2 and Jairo Cajamarca-Baron3, 1Fundacion universitaria de ciencias de la salud, Bogota, Distrito Capital de Bogota, Colombia, 2Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia, 3Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia

    Background/Purpose: Nailfold capillaroscopy is a fundamental tool in rheumatology for assessing capillary morphology, allowing the differentiation between primary and secondary Raynaud’s phenomenon, identifying risks associated…
  • Abstract Number: 1635 • ACR Convergence 2025

    Association Between Treatment Adherence and Frailty in Patients with Rheumatic Diseases

    Daniela L. Guillen-Tejada1, Aura Matilde Jiménez-Garduño1 and Montserrat Lamuño Encorrada2, 1Universidad de las Américas Puebla, Puebla, Mexico, 2Hospital Ángeles Puebla, Puebla, Mexico

    Background/Purpose: Management of rheumatic diseases relies on chronic treatment, often with a greater risk of nonadherence. Frailty is characterized by decreased physiological function that increases patients’…
  • Abstract Number: 1457 • ACR Convergence 2025

    Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study

    Philip J. Mease1, Qi Wei2, Lawrence Huang3, Jason Hawkes4, Clive Liu5, Ying Wu6, Tony Wang7, Anthony Hager8 and Jennifer Hadlock3, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2Institute for Systems Biology, Seattle, WA, 3Institute for Systems Biology, Seattle, 4Oregon Medical Research Center, Portland, OR, 5Bellevue Dermatology, Bellevue, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Meyers Squib, Princeton, NJ, 8Bristol Myers Squibb, Seattle, WA

    Background/Purpose: Real world data from community healthcare systems can provide insights into patient trajectories with psoriasis (PsO) and psoriatic arthritis (PsA): baseline characteristics, patterns of…
  • Abstract Number: 1269 • ACR Convergence 2025

    Dress for success: Influence of Rheumatologist Demographics and Attire on Patients with Chronic Inflammatory Arthritis Perceptions

    LETICIA LEON1, LAURA CANO2, ELENA MORENO3, GABRIELA CASTILLO4, GUIDO CORRADI5, MARTA REDONDO4, MARIA ISABEL CASADO5, DALIFER FREITES6, ALMUDENA TRUCHARTE4, INMACULADA UREÑA2 and lydia Abasolo Alcazar7, 1Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, 2Hospital Regional Universitario de Málaga, MALAGA, Andalucia, Spain, 3Fundación Investigación Biomédica Hospital Clínico San Carlos, MADRID, Madrid, Spain, 4Universidad Camilo Jose Cela, MADRID, Madrid, Spain, 5Universidad Complutense de Madrid, MADRID, Madrid, Spain, 6Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, 7IdISSC. HCSC, Madrid, Madrid, Spain

    Background/Purpose: Physician sociodemographic factors and attire has been shown to influence patients’ trust. This study aimed to determine differences on patient perceptions of rheumatologist professionalism,…
  • Abstract Number: 1255 • ACR Convergence 2025

    Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience

    Reena Yaman1, Lisa Balistreri2, Maximiliano Diaz Menindez3, Sehreen Mumtaz1, Megan Sullivan3, Alexander Hochwald1 and Florentina Berianu1, 1Mayo Clinic Florida, Jacksonville, FL, 2Lee Health, Cape Coral, FL, 3Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
  • Abstract Number: 1174 • ACR Convergence 2025

    High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study

    Mitali Sen1, Gordon Ruan2, Samuel Reynolds3, Haadi Ali3, Xi Yang3, Diana Morlote1, Aishwarya Ravindran1, Lauren Shea1, Matthew Koster4, Jithma Abeykoon2, Hind Salama5, Xin-Xin Cao6, Asra Ahmed3, Ronald Go2 and Gaurav Goyal1, 1University of Alabama at Birmingham, Birmingham, AL, 2Mayo Clinic, Rochester, 3University of Michigan, Michigan, 4Mayo Clinic, Rochester, MN, 5National Guard Health Affairs, Riyadh, Saudi Arabia, 6Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (People's Republic)

    Background/Purpose: Rosai-Dorfman Disease (RDD), formerly known as sinus histiocytosis with massive lymphadenopathy, was initially thought to be inflammatory or autoimmune in nature. The discovery of…
  • Abstract Number: 1158 • ACR Convergence 2025

    Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China

    Guishan Liu1, Jingyuan zhang2, jin Xu2, JiaYuan Dai2 and Min Shen2, 1Peking union medical college hospital, Beijing, Beijing, China (People's Republic), 2Peking union medical college hospital, Beijing, China (People's Republic)

    Background/Purpose: Heterozygous loss-of-function mutations in CTLA4 cause a spectrum of immune dysregulation, characterized by hypogammaglobulinemia, autoimmune cytopenias, and lymphoproliferation, yet penetrance and expressivity remain highly…
  • Abstract Number: 0246 • ACR Convergence 2024

    Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies

    Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
  • Abstract Number: 1131 • ACR Convergence 2024

    Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

    Vivian Laquer1, Leon Kircik2, Neil Sadick3, Jamie Weisman4, Yiwei Zhao5, Jessamyn Blau5, Wenwen Zhang6, Jonathan Uy5, Warren Winkelman6 and Melinda Gooderham7, 1First OC Dermatology Research, Fountain Valley, CA, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Weill Cornell Medical College, New York, NY, 4Piedmont Atlanta, Atlanta, GA, 5Takeda Development Center Americas, Inc., Cambridge, MA, 6Takeda Development Center Americas, Inc., Cambridge, 7SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada

    Background/Purpose: Zasocitinib (TAK-279) is a highly selective, allosteric, oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 mediates signaling from cytokines involved in the pathogenesis of…
  • Abstract Number: 0287 • ACR Convergence 2024

    Joint Involvement in Cystic Fibrosis: Description of Clinical Phenotypes

    Omar Al Tabaa1, manon Lesturgie1, Pierre Régis Burgel2, Nicolas Carlier2 and Jérôme Avouac3, 1Rheumatology Department, Cochin Hospital, Paris, France, 2Pulmonology department, Cochin Hospital, Paris, France, 3Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Cystic fibrosis (CF) is the most common lethal autosomal recessive genetic disorder. The improvement in life expectancy due to the advent of new treatments…
  • Abstract Number: 1224 • ACR Convergence 2024

    Occupational Stress and Fibromyalgia Among Healthcare Professionals in Abu Dhabi Region, United Arab Emirates: A Cross-sectional Study

    Shamma Al Nokhatha1, Asma Alneyadi2, Noor Alnuaimi3, Hajar Almansoori3, Sara Alhosani3, Shammah Almemari4 and Muhammad Hashim3, 1Tawam hospital/ College of Medicine and Health Sciences, Al Ain, Abu Dhabi, United Arab Emirates, 2Tawam hospital, Al Ain, Abu Dhabi, United Arab Emirates, 3College of Medicine and Health Sciences, Al Ain, Abu Dhabi, United Arab Emirates, 4Ambulatory Health Services, Al Ain, Abu Dhabi, United Arab Emirates

    Background/Purpose: The stress level of healthcare workers may impact the quality of care provided to patients. The prevalence of occupational stress among healthcare workers can…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology